...
首页> 外文期刊>Journal of Neuroscience Research >The Selective Noradrenergic Reuptake Inhibitor Reboxetine Restores Spatial Learning Deficits, Biochemical Changes, and Hippocampal Synaptic Plasticity in an Animal Model of Depression
【24h】

The Selective Noradrenergic Reuptake Inhibitor Reboxetine Restores Spatial Learning Deficits, Biochemical Changes, and Hippocampal Synaptic Plasticity in an Animal Model of Depression

机译:在抑郁症动物模型中,选择性去甲肾上腺素再摄取抑制剂瑞波西汀可恢复空间学习缺陷,生化变化和海马突触可塑性。

获取原文
获取原文并翻译 | 示例
           

摘要

Depression is a major psychiatric illness that is associated with cognitive dysfunctions. The underlying mechanism of depression-associated memory impairment is unclear. Previously, we showed altered hippocampal synaptic plasticity in an animal model of depression. Although several antidepressants are beneficial in the treatment of depression, very little is known about the effects of these drugs on depression-associated learning and memory deficits. Prolonged antidepressant treatment might contribute to neuroplastic changes required for clinical outcomes. Accordingly, we evaluated the effect of chronic reboxetine (a selective noradrenergic reuptake inhibitor) treatment on depression-induced reduced hippocampal synaptic plasticity, neurotransmitter levels, and spatial learning and memory impairments. Depression was induced in male Wistar rats by the administration of clomipramine from postnatal days 8 to 21, and these rats were treated with reboxetine in adulthood. The neonatal clomipramine administration resulted in impaired hippocampal long-term potentiation (LTP), decreased hippocampal cholinergic activity and monoamine levels, and poor performance in a partially baited eight-arm radial maze task. Chronic reboxetine treatment restored the hippocampal LTP, acetylcholinesterase activity, and levels of biogenic amines and ameliorated spatial learning and memory deficits in the depressed state. Thus, restoration of hippocampal synaptic plasticity might be a cellular mechanism underlying the beneficial effect of reboxetine in depression-associated cognitive deficits. This study furthers the existing understanding of the effects of antidepressants on learning, memory, and synaptic plasticity and could ultimately assist in the development of better therapeutic strategies to treat depression and associated cognitive impairments. (c) 2014 Wiley Periodicals, Inc.
机译:抑郁症是一种主要的精神疾病,与认知功能障碍有关。抑郁相关的记忆障碍的潜在机制尚不清楚。以前,我们在抑郁动物模型中显示了海马突触可塑性改变。尽管几种抗抑郁药对抑郁症的治疗有益,但对这些药物对与抑郁症相关的学习和记忆障碍的作用知之甚少。长期的抗抑郁治疗可能会导致临床结果所需的神经增生性改变。因此,我们评估了慢性瑞波西汀(选择性去甲肾上腺素再摄取抑制剂)对抑郁症引起的海马突触可塑性,神经递质水平以及空间学习和记忆障碍的减轻作用。从出生后第8天到第21天服用氯米帕明可诱导雄性Wistar大鼠抑郁,这些大鼠在成年后接受瑞波西汀治疗。新生儿服用氯米帕明导致海马长期增强能力(LTP)受损,海马胆碱能活性和单胺水平降低,以及在部分诱饵的八臂radial骨迷宫任务中表现不佳。慢性瑞波西汀治疗可在抑郁状态下恢复海马LTP,乙酰胆碱酯酶活性和生物胺水平,并改善空间学习和记忆障碍。因此,海马突触可塑性的恢复可能是瑞波西汀在与抑郁相关的认知缺陷中有益作用的细胞机制。这项研究进一步了解了抗抑郁药对学习,记忆和突触可塑性的影响,并最终有助于开发更好的治疗策略来治疗抑郁症和相关的认知障碍。 (c)2014年威利期刊有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号